Schrödinger, Inc. (SDGR) compared with its closest peers (RCUS, LGND, KROS, AKBA, ANAB). Peer set by Pharmaceutical Products; 10 comparable drugmakers. First-party data.
Arcus Biosciences, Ligand Pharmaceuticals, Keros Therapeutics, Akebia Therapeutics, AnaptysBio, LifeVantage, Puma Biotechnology, Xeris Biopharma, Rigel Pharmaceuticals and Ironwood Pharmaceuticals share Schrödinger's sub-industry, pharmaceutical makers.
| Company | Market Cap | P/E |
|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | $3.82B | -7.2 |
| Ligand Pharmaceuticals Incorporated (LGND) | $5.70B | 41.0 |
| Keros Therapeutics, Inc. (KROS) | $219.29M | 8.8 |
| Akebia Therapeutics, Inc. (AKBA) | $243.63M | -80.3 |
| AnaptysBio, Inc. (ANAB) | $1.68B | -105.4 |
| LifeVantage Corporation (LFVN) | $84.02M | 11.6 |
| Puma Biotechnology, Inc. (PBYI) | $476.97M | 17.9 |
| Xeris Biopharma Holdings, Inc. (XERS) | $1.50B | — |
| Rigel Pharmaceuticals, Inc. (RIGL) | $857.22M | 13.7 |
| Ironwood Pharmaceuticals, Inc. (IRWD) | $708.05M | 4.1 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
SDGR overview · SDGR earnings · SDGR financials · SDGR KPIs · SDGR documents · SDGR ownership
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.